Does Dr. LINDA LUNDBLAD have financial conflicts of interest?

Dr. LINDA LUNDBLAD (RN CNS APRN) has received a total of $443 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $443 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. LINDA LUNDBLAD?

According to CMS Open Payments data, Dr. LINDA LUNDBLAD received funding from ITI, . (D/B/A INTRA-CELLULAR THERAPIES, .) ($245), ITI ($161), and TAKEDA PHARMACEUTICALS U.S.A ($36).

Does Dr. LINDA LUNDBLAD receive research grants or speaking fees?

Dr. LINDA LUNDBLAD has received $443 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. LINDA LUNDBLAD

RN CNS APRNReal-Time Hydrated

Specialty: Clinical Nurse Specialist, Psych/Mental Health, Adult

Practice Location: HINGHAM, MA 02043

NPI Number: 1285780247

LIFETIME INDUSTRY VALUE

$443

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. LUNDBLAD is a verified Clinical Nurse Specialist, Psych/Mental Health, Adult practitioner based in HINGHAM, MA.

Between 2021 and 2025, Dr. LUNDBLAD had an overall industry promotional and research financial footprint of $443 as recorded in the federal CMS Open Payments database.

$443 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. LUNDBLAD's primary funding source is ITI, . (D/B/A INTRA-CELLULAR THERAPIES, .), which accounts for $245 (representing 55.4% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ITI, . (D/B/A INTRA-CELLULAR THERAPIES, .)

Rank 1

$245

55.4%

ITI

Rank 2

$161

36.4%

TAKEDA PHARMACEUTICALS U.S.A

Rank 3

$36

8.2%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.